Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -146.87% | -733.33% | 2.98% | 36.82% | 135.24% |
| Total Depreciation and Amortization | 1.13% | -8.48% | -13.67% | -10.53% | -13.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 371.17% | 561.67% | 2.34% | 100.00% | -90.02% |
| Change in Net Operating Assets | -183.90% | 239.65% | -104.72% | -42.41% | -16.09% |
| Cash from Operations | -51.44% | 13,760.00% | -68.21% | 14.48% | 21.69% |
| Capital Expenditure | -8.40% | 0.67% | 18.49% | 10.79% | 16.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 280.00% | -98.21% | -- | -100.00% |
| Other Investing Activities | -22.14% | 17.03% | -24.93% | -11.01% | 46.34% |
| Cash from Investing | -32.89% | 45.65% | -41.06% | -20.44% | 79.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -37.00% | -- | -- | -- | 29.38% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 114.47% | -- | 81.82% | -2,920.00% | -2,433.33% |
| Cash from Financing | -17.01% | -- | -1,656.36% | 78.61% | 18.99% |
| Foreign Exchange rate Adjustments | -277.94% | 403.03% | 36.36% | -966.67% | -53.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -101.94% | 352.62% | -248.38% | 64.13% | 69.62% |
